Biopharma Daily Stock Updates - 01/12/21

Updated: Jan 13

$XBI $149.35 (+0.87%) 📈


COVID:

$MRNA (+6.22%) - Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland

https://investors.modernatx.com/news-releases/news-release-details/swissmedic-authorizes-covid-19-vaccine-moderna-use-switzerland


PIPELINE:

$MESO (-10.18%) - CHF Phase 3 Trial Results Presented at Investor Conference

http://investorsmedia.mesoblast.com/static-files/8ac58479-2a71-40f7-9605-10f15fdb45b1


$MIRM (+5.04%) - News Release Details Mirum Pharmaceuticals Provides Corporate Update

https://mirumpharma.gcs-web.com/news-releases/news-release-details/mirum-pharmaceuticals-provides-corporate-update


$TVTX (+1.07%) - Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy

https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announces-orphan-drug-designation


$MRUS (+20.30%) - Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium

https://ir.merus.nl/news-releases/news-release-details/merus-announces-presentation-phase-1-clinical-data-mcla-158


$OTLK (-1.59%) - Leading Ophthalmology Organization Launches Podcast Video with Firas Rahhal, MD, to Explore the Genesis and Promise of Outlook Therapeutics’ ONS-5010/LYTENAVA™ (bevacizumab-vikg)

http://ir.outlooktherapeutics.com/news-releases/news-release-details/leading-ophthalmology-organization-launches-podcast-video-firas


FINANCIAL:

$MNOV (+0.54%) - MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners

https://investors.medicinova.com/news-releases/news-release-details/medicinova-enters-us20-million-securities-purchase-agreement


$CERC (+8.87%) - Closed offering priced at $2.60/share

https://ir.cerecor.com/press-releases/detail/117


$RGNX (+1.27%) - Closed offering priced at $47/share

http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-closing-public-offering-common-stock-and-0


$RDHL (-13.66%) - RedHill Biopharma Increases Previously Announced Bought Deal to $25 Million

https://ir.redhillbio.com/news-releases/news-release-details/redhill-biopharma-increases-previously-announced-bought-deal-25


0 comments

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon